[go: up one dir, main page]

PE20070115A1 - Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas - Google Patents

Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas

Info

Publication number
PE20070115A1
PE20070115A1 PE2006000662A PE2006000662A PE20070115A1 PE 20070115 A1 PE20070115 A1 PE 20070115A1 PE 2006000662 A PE2006000662 A PE 2006000662A PE 2006000662 A PE2006000662 A PE 2006000662A PE 20070115 A1 PE20070115 A1 PE 20070115A1
Authority
PE
Peru
Prior art keywords
alkyl
aspartile
inhibitors
heteroarylalkyl
arylalkyl
Prior art date
Application number
PE2006000662A
Other languages
English (en)
Inventor
Andrew Stamford
Zhaoning Zhu
Brian Mckittrick
Elizabeth M Smith
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37388420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070115(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20070115A1 publication Critical patent/PE20070115A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/72—Heterocyclic compounds containing 1,3,5-triazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A ES UN ENLACE, -CO-, CH2, ENTRE OTROS; X ES -NR1, CR6R7; Y ES -SO2-, -C(=O)-, -PO(OR9), -C(R6'R7'); ---- ES UN ENLACE SIMPLE O DOBLE; R3 Y R4 SON CADA UNO H, ALQUILO, HETEROARILALQUILO, HETEROCICLOALQUILALQUILO, ENTRE OTROS; R1, R2 Y R5 SON CADA UNO H, ALQUILO, ARILALQUILO, HETEROARILALQUILO, CICLOALQUILALQUILO, ENTRE OTROS; R6, R6', R7 Y R7' SON CADA UNO H, ALQUILO, ARILALQUILO, HETEROARILALQUILO, CICLOALQUILO, ENTRE OTROS; R9 ES H, ALQUILO, ALQUENILO, CICLOALQUILO, ARILO, ARILALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1, 2; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE ASPARTIL ASPARASAS UTILES EN EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES, ENFERMEDADES COGNITIVAS Y NEURODEGENERATIVAS, ENTRE OTROS
PE2006000662A 2005-06-14 2006-06-13 Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas PE20070115A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69041305P 2005-06-14 2005-06-14

Publications (1)

Publication Number Publication Date
PE20070115A1 true PE20070115A1 (es) 2007-02-13

Family

ID=37388420

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000662A PE20070115A1 (es) 2005-06-14 2006-06-13 Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas

Country Status (16)

Country Link
US (1) US8110682B2 (es)
EP (2) EP2194047A1 (es)
JP (1) JP4859922B2 (es)
KR (1) KR20080015861A (es)
CN (1) CN101198597B (es)
AR (1) AR054510A1 (es)
AT (1) ATE489370T1 (es)
AU (1) AU2006259574A1 (es)
CA (1) CA2610829A1 (es)
DE (1) DE602006018456D1 (es)
IL (1) IL187453A0 (es)
MX (1) MX2007016177A (es)
PE (1) PE20070115A1 (es)
TW (1) TW200716574A (es)
WO (1) WO2006138266A2 (es)
ZA (1) ZA200710342B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
AR054620A1 (es) * 2005-06-14 2007-07-04 Schering Corp Inhibidores de aspartil proteasas
EP1896478B1 (en) 2005-06-14 2014-05-21 Merck Sharp & Dohme Corp. Aspartyl protease inhibitors
EP1896032B1 (en) 2005-06-14 2012-10-31 Merck Sharp & Dohme Corp. The preparation and use of compounds as protease inhibitors
WO2007050721A2 (en) 2005-10-27 2007-05-03 Schering Corporation Heterocyclic aspartyl protease inhibitors
AU2007258435A1 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
AU2007332754A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
EP2200990A1 (en) 2007-09-06 2010-06-30 Schering Corporation Gamma secretase modulators
EP2217604A1 (en) 2007-11-05 2010-08-18 Schering Corporation Gamma secretase modulators
EP2227471A1 (en) * 2007-12-11 2010-09-15 Schering Corporation Gamma secretase modulators
CN102282145A (zh) 2008-11-13 2011-12-14 先灵公司 γ分泌酶调节剂
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
CA2747750A1 (en) 2008-12-22 2010-07-01 Theodros Asberom Gamma secretase modulators
EP2379563B1 (en) 2008-12-22 2014-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
EP2443119A1 (en) 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
WO2010147973A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
WO2011044184A1 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
US8563543B2 (en) 2009-10-08 2013-10-22 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
JP2013542973A (ja) 2010-11-22 2013-11-28 ノスシラ、ソシエダッド、アノニマ 神経変性疾患または神経変性状態を治療するためのビピリジンスルホンアミド誘導体
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
WO2012138590A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
RU2014111055A (ru) 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
CA2867891C (en) 2012-03-19 2021-09-14 Buck Institute For Research On Aging App specific bace inhibitors (asbis) and uses thereof
WO2014062553A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2014062549A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
ES2769578T3 (es) 2013-02-12 2020-06-26 Buck Inst Res Aging Hidantoínas que modulan el procesamiento de APP mediado por BACE
EP2781919A1 (en) 2013-03-19 2014-09-24 Roche Diagniostics GmbH Method / device for generating a corrected value of an analyte concentration in a sample of a body fluid
WO2015095104A1 (en) 2013-12-18 2015-06-25 Merck Sharp & Dohme Corp. Iminothiadiazepane dioxide compounds as bace inhibitors, compositions, and their use
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
CN110198935B (zh) 2017-01-23 2022-05-31 卡登特治疗公司 钾通道调节剂
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
MA53978A (fr) 2018-10-22 2021-09-01 Cadent Therapeutics Inc Formes cristallines de modulateurs des canaux potassiques
CA3185040A1 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1077204A (en) 1912-11-20 1913-10-28 John Bonner Semple Tracer for projectiles.
US3287366A (en) * 1963-12-24 1966-11-22 American Cyanamid Co Novel 1, 2-dihydro-s-triazines
US3287365A (en) * 1963-12-24 1966-11-22 American Cyanamid Co Novel dihydro-s-triazines and method of preparation
US3876785A (en) * 1967-12-06 1975-04-08 Beecham Group Ltd 4,6-diamino-1,2-dihydro-arylmethoxy-1,3,5-triazines for combating plasmodium parasites
GB1217415A (en) * 1968-07-04 1970-12-31 Vitamins Ltd Triazine derivatives and pharmaceutical formulation and processes for making same
US3723429A (en) * 1969-11-06 1973-03-27 Beecham Group Ltd Di-hydro triazine derivatives
US3682912A (en) * 1969-12-18 1972-08-08 Beecham Group Ltd Di-hydro triazine derivatives
US6232309B1 (en) * 1989-03-09 2001-05-15 Nihon Bayer Agrochem K.K. Insecticidal heterocyclic compounds
AU2436792A (en) 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5565451A (en) * 1994-09-15 1996-10-15 Fmc Corporation 1-substituted-2, 4-diamino-6, 6-dialkyl-1, 6-dihydro-1, 3, 5-triazines as insecticides
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5935958A (en) 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
RU2252937C2 (ru) * 1998-12-01 2005-05-27 Нихон Байер Агрохем К.К. Производные 1,3,5-триазина, гербицидная композиция на их основе и промежуточные соединения
US6294554B1 (en) 1999-09-22 2001-09-25 Schering Corporation Muscarinic antagonists
GB0001565D0 (en) * 2000-01-24 2000-03-15 Isis Innovation Dihydrofolate reductase inhibitors
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
AU2001264385A1 (en) * 2000-07-07 2002-01-21 Lg Life Sciences Ltd Novel cephalosporin compounds and process for preparing the same
JP4012068B2 (ja) 2000-12-22 2007-11-21 シェーリング コーポレイション ムスカリンアンタゴニスト
AU2002306734A1 (en) 2001-03-15 2002-10-03 The Johns Hopkins University Inhibitors of plasmepsins
GB0123467D0 (en) * 2001-09-28 2001-11-21 Hoffmann La Roche Carbocyclic HIV Protease inhibitors
CN1301972C (zh) 2001-10-10 2007-02-28 先灵公司 作为毒覃碱拮抗剂的哌啶化合物
US7818327B2 (en) * 2002-09-06 2010-10-19 Infineon Technologies Ag Method and system for determining conformance of a data key with rules by means of memory lookups
CA2499036A1 (en) * 2002-09-24 2004-04-08 Koronis Pharmaceuticals, Incorporated 1,3,5-triazines for treatment of viral diseases
US7256218B2 (en) * 2002-11-22 2007-08-14 Jacobus Pharmaceutical Company, Inc. Biguanide and dihydrotriazine derivatives
US7622469B2 (en) * 2002-12-17 2009-11-24 Hamari Chemicals, Ltd. 2,4-diamino-1,3,5-triazine derivatives
SG146624A1 (en) * 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
DE10348023A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US20050123906A1 (en) * 2003-11-06 2005-06-09 Rana Tariq M. Protein modulation
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
JP2007534697A (ja) * 2004-04-27 2007-11-29 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ ミコフェノール酸モフェチルおよび他のミコフェノール酸エステルの調製方法
WO2006009655A1 (en) 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
MXPA06014793A (es) 2004-06-16 2007-02-16 Wyeth Corp Derivados de amino-5, 5-difenilimidazolona para la inhibicion de ??-secretasa.
AU2005295814A1 (en) 2004-10-13 2006-04-27 Merck & Co., Inc. Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of Alzhermer's disease
WO2006044492A2 (en) 2004-10-14 2006-04-27 Ingenious Targeting Laboratory, Inc. Methods for generating rat embryo-derived cell lines and genetic modification of rat genome
JP2008516945A (ja) 2004-10-15 2008-05-22 アストラゼネカ・アクチエボラーグ 置換されたアミノ化合物およびそれらの使用

Also Published As

Publication number Publication date
CN101198597A (zh) 2008-06-11
JP2008546697A (ja) 2008-12-25
US20070010667A1 (en) 2007-01-11
EP1896430B1 (en) 2010-11-24
WO2006138266A3 (en) 2007-03-08
EP2194047A1 (en) 2010-06-09
ATE489370T1 (de) 2010-12-15
EP1896430A2 (en) 2008-03-12
ZA200710342B (en) 2008-12-31
CN101198597B (zh) 2011-11-16
TW200716574A (en) 2007-05-01
KR20080015861A (ko) 2008-02-20
AR054510A1 (es) 2007-06-27
CA2610829A1 (en) 2006-12-28
US8110682B2 (en) 2012-02-07
DE602006018456D1 (de) 2011-01-05
MX2007016177A (es) 2008-03-07
IL187453A0 (en) 2008-02-09
JP4859922B2 (ja) 2012-01-25
AU2006259574A1 (en) 2006-12-28
WO2006138266A2 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20070138A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
PE20070531A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
PE20070135A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
PE20070073A1 (es) Compuestos heterociclicos como inhibidores de proteasas
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
PE20051048A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasa
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20070321A1 (es) Compuestos heterociclicos como inhibidores de proteasas
PE20070798A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
PE20070078A1 (es) Compuestos heterociclicos macrociclicos como inhibidores de aspartil proteasa
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
EA200700141A1 (ru) Новые аминоциклические производные мочевины, их получение и фармацевтическое применение в качестве ингибиторов киназы
PE20070018A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
PE20051046A1 (es) Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
ATE478044T1 (de) Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
PE20090435A1 (es) Inhibidores de tetrahidropiranocromeno de gamma secretasa
PE20060693A1 (es) Nuevos derivados de trifluorometansulfonanilida oxamida eter
BRPI0514738A (pt) derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
PE20090042A1 (es) Analogos de ciclopamina
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
PE20121157A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed